

IN THE CLAIMS:

(All claims are reproduced for the Examiner's convenience. Claims that have not been amended are indicated as "Unchanged.")

A1
1. (Unchanged) A vaccine useful for the treatment of melanoma comprising irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl, tritylphenyl, and N-iodoacetyl-N'-5 sulfonic 1-naphthyl ethylene diamine; and mixed with an immunological adjuvant, wherein said immunological adjuvant is *Bacille Calmette-Guerin.*

Dub
2. (Unchanged) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of the vaccine of claim 1.

Please add the following new claims:

A2
--3. (New) The vaccine of claim 1, wherein said autologous melanoma cells are cryopreserved.

--4. (New) The vaccine of claim 1, wherein said autologous melanoma cells are irradiated with a low radiation dose.

4
--5. (New) The method of claim 2, wherein said autologous melanoma cells are cryopreserved.

--6. (New) The method of claim 2, wherein said vaccine is injected at multiple sites per administration.

Pub D
--7. (New) The method of claim 2, wherein said vaccine is injected into three contiguous sites on an upper arm or leg.

--8. (New) The method of claim 2, wherein said vaccine is administered to post-surgical melanoma patients.

--9. (New) The method of claim 2, wherein said vaccine is administered to stage four melanoma patients.

--10. (New) The method of claim 2, wherein said autologous melanoma cells are irradiated with a low radiation dose.

--11. (New) The method of claim 2, further comprising multiple intradermal administrations every 4 weeks.

--12. (New) The method of claim 2, further comprising more than two intradermal administrations.

--13. (New) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of a vaccine composition comprising cryopreserved and irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl, tritylphenyl, and N-iodoacetyl-N'-5 sulfonic 1-naphthyl ethylene diamine and mixed with *Bacille Calmette-Guerin*.

--14. (New) The method of claim 13, wherein said vaccine is injected at multiple sites per administration.

sub D²
--15. (New) The method of claim 14, wherein said vaccine is injected into 3 contiguous sites on an upper arm or leg.

--16. (New) The method of claim 13, wherein said vaccine is administered to post-surgical melanoma patients.

--17. (New) The method of claim 13, wherein said vaccine is administered to stage four melanoma patients.

--18. (New) The method of claim 13, wherein said autologous melanoma cells are irradiated with a low radiation dose.